Guadalupe Garcia-Tsao

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi request reprint The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites
    Guadalupe Garcia-Tsao
    Yale University School of Medicine, New Haven, CT 06510, USA
    Nat Clin Pract Gastroenterol Hepatol 3:380-9. 2006
  2. ncbi request reprint Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Yale University School of Medicine and VA CT Healthcare System, New Haven, Connecticut 06520, USA
    Am J Gastroenterol 102:2086-102. 2007
  3. ncbi request reprint Portal hypertension and hepatocellular carcinoma: prognosis and beyond
    Puneeta Tandon
    Clin Gastroenterol Hepatol 4:1318-9. 2006
  4. ncbi request reprint Probiotics and liver disease
    Anish A Sheth
    Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06520 8000, USA
    J Clin Gastroenterol 42:S80-4. 2008
  5. pmc Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies
    Puneeta Tandon
    Digestive Diseases Section, Yale University School of Medicine, New Haven, CT, USA
    Liver Int 29:502-10. 2009
  6. ncbi request reprint Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program
    Guadalupe Garcia-Tsao
    Department of Veterans Affairs Medical Center, West Haven, Connecticut, USA
    Am J Gastroenterol 104:1802-29. 2009
  7. ncbi request reprint Portal hypertension
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06510, USA
    Curr Opin Gastroenterol 21:313-22. 2005
  8. ncbi request reprint Portal hypertension
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Yale University School of Medicine and Connecticut VA, Healthcare System, New Haven, 06510, USA
    Curr Opin Gastroenterol 22:254-62. 2006
  9. ncbi request reprint Liver involvement in hereditary hemorrhagic telangiectasia (HHT)
    Guadalupe Garcia-Tsao
    Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine and VA CT Healthcare System, 333 Cedar Street 1080 LMP, P O Box 208019, New Haven, CT 06520, USA
    J Hepatol 46:499-507. 2007
  10. ncbi request reprint Preventing the development of varices in cirrhosis
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA
    J Clin Gastroenterol 41:S300-4. 2007

Research Grants

  1. CIRRHOSIS AND ITS COMPLICATIONS
    Guadalupe Garcia Tsao; Fiscal Year: 2007

Detail Information

Publications68

  1. ncbi request reprint The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites
    Guadalupe Garcia-Tsao
    Yale University School of Medicine, New Haven, CT 06510, USA
    Nat Clin Pract Gastroenterol Hepatol 3:380-9. 2006
    ....
  2. ncbi request reprint Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Yale University School of Medicine and VA CT Healthcare System, New Haven, Connecticut 06520, USA
    Am J Gastroenterol 102:2086-102. 2007
  3. ncbi request reprint Portal hypertension and hepatocellular carcinoma: prognosis and beyond
    Puneeta Tandon
    Clin Gastroenterol Hepatol 4:1318-9. 2006
  4. ncbi request reprint Probiotics and liver disease
    Anish A Sheth
    Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06520 8000, USA
    J Clin Gastroenterol 42:S80-4. 2008
    ..The role of probiotics is examined in the following areas: a) prevention of infection, b) the hyperdynamic circulatory state of cirrhosis, c) hepatic encephalopathy, d) liver function, and e) nonalcoholic fatty liver disease...
  5. pmc Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies
    Puneeta Tandon
    Digestive Diseases Section, Yale University School of Medicine, New Haven, CT, USA
    Liver Int 29:502-10. 2009
    ..Although there are many studies of the predictors of death in hepatocellular carcinoma (HCC), most combine patients with and without cirrhosis and many combine those with compensated and decompensated cirrhosis...
  6. ncbi request reprint Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program
    Guadalupe Garcia-Tsao
    Department of Veterans Affairs Medical Center, West Haven, Connecticut, USA
    Am J Gastroenterol 104:1802-29. 2009
    ..A rational management of cirrhosis will result in improvements in quality of life, treatment adherence, and, ultimately, in outcomes...
  7. ncbi request reprint Portal hypertension
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06510, USA
    Curr Opin Gastroenterol 21:313-22. 2005
    ..Report on significant advances in the pathophysiology, diagnosis, and management of the complications of portal hypertension that have occurred in the last year...
  8. ncbi request reprint Portal hypertension
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Yale University School of Medicine and Connecticut VA, Healthcare System, New Haven, 06510, USA
    Curr Opin Gastroenterol 22:254-62. 2006
    ..Significant advances in the pathophysiology, diagnosis and management of the complications of portal hypertension that have occurred in the last year are reported...
  9. ncbi request reprint Liver involvement in hereditary hemorrhagic telangiectasia (HHT)
    Guadalupe Garcia-Tsao
    Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine and VA CT Healthcare System, 333 Cedar Street 1080 LMP, P O Box 208019, New Haven, CT 06520, USA
    J Hepatol 46:499-507. 2007
    ..Papers were considered if they were published in English and if they included specific cases that were sufficiently described...
  10. ncbi request reprint Preventing the development of varices in cirrhosis
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA
    J Clin Gastroenterol 41:S300-4. 2007
    ....
  11. ncbi request reprint Treatment of gastropathy and gastric antral vascular ectasia in patients with portal hypertension
    Cristina Ripoll
    Guadalupe Garcia Tsao, MD Digestive Diseases Section, Yale University School of Medicine, 333 Cedar Street 1080 LMP, New Haven, CT 06510, USA
    Curr Treat Options Gastroenterol 10:483-94. 2007
    ..Preliminary data suggest that cryotherapy may be a reasonable option for diffuse GAVE lesions. Neither beta-blockers nor TIPS reduces the bleeding risk in patients with GAVE and thus should not be used in this setting...
  12. doi request reprint Portal hypertension and variceal bleeding--unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Hepatology 47:1764-72. 2008
  13. doi request reprint Acute kidney injury in cirrhosis
    Guadalupe Garcia-Tsao
    Section of Digestives Diseases, Yale University School of Medicine, New Haven, CT, USA
    Hepatology 48:2064-77. 2008
    ..Vasoconstrictors are useful bridging therapies in HRS. Ultimately, liver transplantation is indicated in otherwise reasonable candidates in whom AKI does not resolve with specific therapy...
  14. ncbi request reprint Bacterial infections in cirrhosis: treatment and prophylaxis
    Guadalupe Garcia-Tsao
    Department of Digestive Diseases, Yale University, New Haven, CT 06620, USA
    J Hepatol 42:S85-92. 2005
  15. ncbi request reprint Difficult management decision
    Guadalupe Garcia-Tsao
    Liver Study Unit, Yale School of Medicine, New Haven, Connecticut 06520, USA
    J Clin Gastroenterol 35:S143-6. 2002
  16. ncbi request reprint Bacterial infections in cirrhosis
    Guadalupe Garcia-Tsao
    Yale University School of Medicine, New Haven, Connecticut 06520 8019, USA
    Can J Gastroenterol 18:405-6. 2004
    ..Patients who recover from an episode of SBP should be given long term prophylaxis with norfloxacin and should be assessed for liver transplantation...
  17. ncbi request reprint Gut microflora in the pathogenesis of the complications of cirrhosis
    Guadalupe Garcia-Tsao
    Gastroenterology Service, VA Connecticut Healthcare System and Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar Street 1080 LMP, P O Box 3333, New Haven, CT 06520 8019, USA
    Best Pract Res Clin Gastroenterol 18:353-72. 2004
    ..This chapter presents evidence regarding gut flora and its modification in the pathogenesis and management of these complications of cirrhosis...
  18. ncbi request reprint Liver disease in patients with hereditary hemorrhagic telangiectasia
    G Garcia-Tsao
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn 06520, USA
    N Engl J Med 343:931-6. 2000
    ..Liver involvement in patients with this disease has not been fully characterized...
  19. ncbi request reprint Spontaneous bacterial peritonitis: a historical perspective
    Guadalupe Garcia-Tsao
    Yale University School of Medicine and CT VA Healthcare System, 333 Cedar Street, New Haven, CT 06510, USA
    J Hepatol 41:522-7. 2004
  20. ncbi request reprint Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis
    Cristina Ripoll
    Veterans Affairs CT Healthcare System, Yale University School of Medicine, West Haven, Connecticut 06516, USA
    Gastroenterology 133:481-8. 2007
    ....
  21. pmc Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan, USA
    Gut 59:1401-9. 2010
    ..The aim of this study was to explore the association of serum fibrosis marker levels with the risk of clinical and histological disease progression in a large cohort of patients with chronic hepatitis C (CHC)...
  22. pmc Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis
    Cristina Ripoll
    Veterans Affairs CT Healthcare System, West Haven, CT 06516, USA
    J Hepatol 50:923-8. 2009
    ..Predictors of the development of hepatocellular carcinoma (HCC), including hepatic venous pressure gradient (HVPG) were analyzed...
  23. pmc Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1
    Thomas D Boyer
    Liver Research Institute, Department of Internal Medicine, University of Arizona College of Medicine, Tucson, AZ 85724, USA
    Liver Transpl 17:1328-32. 2011
    ..For patients not undergoing transplantation, HRS reversal with terlipressin and/or albumin improves survival...
  24. ncbi request reprint What do patients consider when making decisions about treatment for hepatitis C?
    Liana Fraenkel
    Department of Medicine, VA Connecticut Healthcare System, West Haven, Conn, USA
    Am J Med 118:1387-91. 2005
    ..In this study, we sought to investigate the factors that influence patients' decisions as they consider treatment for hepatitis C infection...
  25. pmc Patients' preferences for treatment of hepatitis C
    Liana Fraenkel
    VA Connecticut Healthcare System and Yale University School of Medicine, New Haven, Connecticut, USA
    Med Decis Making 30:45-57. 2010
    ..The objective of this study was to ascertain patient preferences for treatment of hepatitis C virus (HCV)...
  26. pmc Quantitative histological-hemodynamic correlations in cirrhosis
    Supatsri Sethasine
    Section of Digestive Diseases, Yale University and VA CT Healthcare System, West Haven, CT, USA
    Hepatology 55:1146-53. 2012
    ..Beyond pathophysiological implications, this also has methodological implications that are discussed in this article...
  27. ncbi request reprint Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis
    Roberto J Groszmann
    Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516, USA
    N Engl J Med 353:2254-61. 2005
    ..Nonselective beta-adrenergic blockers decrease portal pressure and prevent variceal hemorrhage. Their effectiveness in preventing varices is unknown...
  28. pmc The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis
    Khurram Bari
    Digestive Diseases, Yale University School of Medicine, New Haven, CT 06516, USA
    Clin Gastroenterol Hepatol 10:1169-75. 2012
    ..Vasoconstrictors could be used instead of albumin and, with longer use, prevent PCD and delay ascites recurrence...
  29. pmc Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis
    Puneeta Tandon
    Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Gastroenterol Hepatol 8:546-9. 2010
    ..The aim of this study was to evaluate the effect of sildenafil on systemic and portal hemodynamics in an open-label pilot study...
  30. pmc Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C
    Richard W Lambrecht
    Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA
    Gastroenterology 140:1490-500.e3. 2011
    ..Our aim was to assess the relationship of iron and HFE genetic variations to progression and outcomes in the HALT-C Trial and whether PegIFN therapy influenced iron variables...
  31. pmc Acute kidney injury in patients with cirrhosis: perils and promise
    Justin M Belcher
    Program of Applied Translational Research, Yale University School of Medicine, New Haven, Connecticut Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut Clinical Epidemiology Research Center, VA Connecticut Healthcare System, West Haven, Connecticut
    Clin Gastroenterol Hepatol 11:1550-8. 2013
    ..5 mg/dL. Examination of urine sediment showed 1 to 5 bilirubin-stained granular casts per high-powered field and a few renal tubular epithelial cells. The urine sodium level was 21 mEq/L and the fractional excretion of sodium was 0.43%. ..
  32. ncbi request reprint Decompensated cirrhotics have slower intestinal transit times as compared with compensated cirrhotics and healthy controls
    Bani Chander Roland
    Department of Medicine, Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine Yale School of Public Health, Yale Center of Analytical Science, New Haven, CT University Medical Center of Princeton, Princeton, NJ
    J Clin Gastroenterol 47:888-93. 2013
    ..Prior studies using antroduodenal manometry to evaluate intestinal motility have shown discrepancies regarding the relationship between dysmotility and the severity of cirrhosis...
  33. pmc A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome
    Arun J Sanyal
    Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
    Gastroenterology 134:1360-8. 2008
    ..The aim of this study was to evaluate the efficacy and safety of terlipressin, a systemic arterial vasoconstrictor, for cirrhosis type 1 HRS...
  34. pmc Association of AKI with mortality and complications in hospitalized patients with cirrhosis
    Justin M Belcher
    Program of Applied Translational Research, Yale University School of Medicine, New Haven, CT 06515, USA
    Hepatology 57:753-62. 2013
    ..8, 95% confidence interval 1.3-11.1)...
  35. ncbi request reprint Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Yale University School of Medicine and VACT Healthcare System, New Haven, CT, USA
    Hepatology 46:922-38. 2007
  36. ncbi request reprint Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis
    Satish Nagula
    Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    J Hepatol 44:111-7. 2006
    ..This study aimed to determine the relationship between specific histological parameters and HVPG in cirrhosis...
  37. pmc Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C
    Anna S Lok
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Hepatology 54:434-42. 2011
    ..7% of controls. HBV DNA was detected in the serum of only one control subject and no patients with HCC. HBV DNA (as a marker of occult HBV infection) was detected in the livers of 10.7% of HCC cases and 23.6% of controls (P=0.18)...
  38. pmc A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage
    Anna V Longacre
    Section of Digestive Disease, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
    Hepatology 47:169-76. 2008
    ..Forty-eight patients were prescribed beta-blockers, two were not given prophylaxis, and three were lost to follow-up...
  39. ncbi request reprint A commonsense approach to esophageal varices
    Anna V Longacre
    Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, 1080 LMP, 333 Cedar Street, New Haven, CT 06520, USA
    Clin Liver Dis 10:613-25, x. 2006
    ..This article describes a practical approach to the management of cirrhotic patients who have gastroesophageal varices...
  40. ncbi request reprint Portal hypertension: from the patient to the molecule and back: a symposium honoring Roberto J. Groszmann, MD
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06520 8019, USA
    J Clin Gastroenterol 41:S243-4. 2007
  41. doi request reprint Managing varices: drugs, bands, and shunts
    Christopher Kenneth Opio
    Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar Street 1080 LMP, New Haven, CT 06510, USA
    Gastroenterol Clin North Am 40:561-79. 2011
    ..However, the specific use of each of these therapies depends on the setting (primary or secondary prophylaxis, treatment of AVH) and on patient characteristics. The indications for each are summarized in Table 4...
  42. pmc Clinical pharmacology of portal hypertension
    Cecilia Minano
    Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar Street, LMP 1080, New Haven, CT 06520, USA
    Gastroenterol Clin North Am 39:681-95. 2010
    ..This article reviews the pathophysiologic bases of the different pharmacologic treatments for portal hypertension in patients with cirrhosis and places them in the context of the natural history of varices and variceal hemorrhage...
  43. pmc Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis
    Puneeta Tandon
    Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Clin Gastroenterol Hepatol 9:260-5. 2011
    ..To improve stratification of patient care, we performed a systematic review to identify the most robust predictors of mortality in cirrhotic patients with SBP...
  44. ncbi request reprint Liver involvement in hereditary hemorrhagic telangiectasia: CT and clinical findings do not correlate in symptomatic patients
    Jim S Wu
    Department of Diagnostic Radiology, Yale University School of Medicine and Yale New Haven Hospital, New Haven, CT, USA
    AJR Am J Roentgenol 187:W399-405. 2006
    ..The purpose of our study was to report the multiphasic CT findings in patients with symptomatic liver involvement by hereditary hemorrhagic telangiectasia (HHT) and to correlate the CT findings with the type of clinical presentation...
  45. ncbi request reprint Prevention and treatment of infections in patients with cirrhosis
    Sahar Ghassemi
    Division of Digestive Diseases, Yale University School of Medicine, VA CT Healthcare System, 333 Cedar St 1080 LMP, PO Box 208019, New Haven, CT 06520, USA
    Best Pract Res Clin Gastroenterol 21:77-93. 2007
    ....
  46. doi request reprint Hepatic vascular malformations in hereditary hemorrhagic telangiectasia
    Sakib Karim Khalid
    Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Semin Liver Dis 28:247-58. 2008
    ..Patients who fail aggressive medical therapy and those with acute biliary/hepatic necrosis should be considered for liver transplantation...
  47. ncbi request reprint Recommendations for probiotic use--2008
    Martin H Floch
    Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06520 8019, USA
    J Clin Gastroenterol 42:S104-8. 2008
    ..Many reports in the "C" recommendations were significant but fell short of receiving stronger ratings because of the size of reported patient studies, and also the factors that limited categories to the "B" rating...
  48. doi request reprint Non-hemorrhagic acute complications associated with cirrhosis and portal hypertension
    Nicole Ming Ming Loo
    Digestive Diseases Section, Department of Medicine, Yale University, New Haven, CT, USA Digestive Diseases Section, Department of Internal Medicine, VA CT Healthcare System, West Haven, CT, USA
    Best Pract Res Clin Gastroenterol 27:665-78. 2013
    ....
  49. pmc Treatment of portal hypertension
    Khurram Bari
    Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, United States
    World J Gastroenterol 18:1166-75. 2012
    ..Prevention of recurrent variceal hemorrhage consists of the combination of β-blockers and endoscopic band ligation...
  50. ncbi request reprint Patients' experiences related to anti-viral treatment for hepatitis C
    Liana Fraenkel
    VA Connecticut Healthcare System, CT, USA
    Patient Educ Couns 62:148-55. 2006
    ..To conduct a qualitative study to elicit patients' descriptions of their own experiences with treatment for hepatitis C (HCV)...
  51. ncbi request reprint Refractory ascites and hepatorenal syndrome
    Guadalupe Garcia-Tsao
    Yale University School of Medicine, New Haven, Cennecticut, USA
    Rev Gastroenterol Mex 69:152-4. 2004
  52. ncbi request reprint Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats
    Reiner Wiest
    Hepatic Hemodynamic Laboratory, Veterans Administration Medical Center, West Haven, CT 06515, USA
    Hepatology 38:1508-15. 2003
    ..69, P <.01). In conclusion, in cirrhotic animals BT appears to lead to endotoxemia, stimulation of GTPCH-I, increased BH(4) synthesis, and further enhancement of vascular NO production that leads to aggravation of vasodilatation...
  53. pmc Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis
    Sakib K Khalid
    Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Clin Gastroenterol Hepatol 7:994-9; quiz 913-4. 2009
    ..We performed a prospective, case-control study to investigate the effects of analgesics on acute hepatic decompensation...
  54. pmc High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center
    Puneeta Tandon
    University of Alberta, Edmonton, Alberta, Canada
    Clin Gastroenterol Hepatol 10:1291-8. 2012
    ..Exposure to systemic antibiotics is a risk factor for AR-BI; however, little is known about the effects of the increasingly used oral nonabsorbed antibiotics...
  55. pmc Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 7:219-26. 2009
    ..Serum fibrosis marker levels during the lead-in treatment phase of patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial were determined...
  56. ncbi request reprint Bacterial translocation (BT) in cirrhosis
    Reiner Wiest
    Department of Internal Medicine I, University of Regensburg Hospital Franz Josef Strauss Allee, Regensburg, Germany
    Hepatology 41:422-33. 2005
    ..Future research in the field of BT in cirrhosis will allow the development of new therapeutic targets in the prevention of infections and other complications of cirrhosis...
  57. ncbi request reprint Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis
    Pere Gines
    Liver Unit, Hospital Clinic, Institut d Investigacions Biomédiques August Pi Sunyer IDIBAPS, University of Barcelona, Instituto Reina Sofia de Investigacion Nefrologica, Barcelona, Catalunya, Spain
    Gastroenterology 123:1839-47. 2002
    ..However, its effect on survival and healthcare costs is still uncertain...
  58. doi request reprint Bacterial infections, sepsis, and multiorgan failure in cirrhosis
    Puneeta Tandon
    Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada
    Semin Liver Dis 28:26-42. 2008
    ..We review the pathogenesis and management of these complications, the role of adrenal insufficiency, and the utility of intensive care prognostic models...
  59. ncbi request reprint Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis
    Amir A Qamar
    Brigham and Women s Hospital, Boston, MA 02446, USA
    Hepatology 47:153-9. 2008
    ..Patients with mild portal hypertension whose PLT remains greater than 100,000 have significantly less risk of GEV. Although HVPG correlates somewhat with PLT, changes in PLT cannot be used as a surrogate for HVPG changes...
  60. ncbi request reprint Endoscopic variceal banding vs. pharmacological therapy for the prevention of recurrent variceal hemorrhage: what makes the difference?
    Roberto J Groszmann
    Gastroenterology 123:1388-91. 2002
  61. ncbi request reprint Spontaneous bacterial peritonitis
    Guadalupe Garcia-Tsao
    Rev Gastroenterol Mex 70:66-8. 2005
  62. ncbi request reprint Multiple angiomyolipomata of the liver: a case report
    Laura H Tang
    Department of Anatomic Pathology, Yale University School of Medicine, New Haven, Connecticut 06511, USA
    Mod Pathol 15:167-71. 2002
    ..While the histologic diagnosis of AML in a surgical resection specimen is often straightforward, the radiographic, cytologic and intra-operative interpretation of a case with multiple lesions presents a considerable challenge...
  63. ncbi request reprint Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States
    Marion G Peters
    University of California at San Francisco, San Francisco, CA 94143 0538, USA
    Hepatology 46:769-75. 2007
    ..However, the mean age, male-to-female ratio, and seroprevalence of AMA positivity were similar between the 2 groups...
  64. pmc Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay
    Marlyn J Mayo
    University of Texas Southwestern Medical Center, Dallas, TX 75390 9151, USA
    Hepatology 48:1549-57. 2008
    ..However, at earlier times in the disease process (4 and 6 years before the first event), the prognostic performance of ELF was significantly better than MELD or Mayo R score...
  65. ncbi request reprint Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies
    Gennaro D'Amico
    Gastroenterology Unit, Ospedale Cervello and University of Palermo, Italy
    J Hepatol 44:217-31. 2006
  66. ncbi request reprint Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis
    Burton Combes
    The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9151, USA
    Hepatology 42:1184-93. 2005
    ..In conclusion, methotrexate when added to UDCA for a median period of 7.6 years had no effect on the course of PBC treated with UDCA alone...
  67. pmc Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis
    Burton Combes
    University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9151, USA
    Am J Gastroenterol 99:264-8. 2004
    ....
  68. doi request reprint Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: in search of predictors of significant disease
    Guadalupe Garcia-Tsao
    Hepatology 48:1377-9. 2008

Research Grants2

  1. CIRRHOSIS AND ITS COMPLICATIONS
    Guadalupe Garcia Tsao; Fiscal Year: 2007
    ..Renewal of the award will allow Dr. Garcia-Tsao to maintain both POR and her mentoring endeavors to their fullest extent so she can continue to make significant contributions in the field of chronic liver disease and its complications. ..